Abstract 1979P
Background
Cancer Immunotherapy Trials Network 12, a phase 1 multicenter study of pembrolizumab (pembro) in advanced HIV-associated cancers showed safety across a range of cancers in patients (pts) with controlled HIV (Uldrick et al. JAMA Oncology 2019 ). We report results from the expanded KS cohort.
Methods
Pts with HIV+ KS, CD4 count (CD4) ≥50 cells/μL, antiretroviral therapy (ART) for ≥4 weeks, HIV viral load ≤200 copies/mL with or without prior KS therapy were eligible. Pts received pembro 200 mg q3 weeks for up to 35 cycles. The primary objective was safety by NCI Common Terminology Criteria for Adverse Events; the secondary objective was KS response rate by AIDS Clinical Trials Group Criteria. Progression-free survival (PFS) and duration of response (DOR) were evaluated by Kaplan-Meier (KM) methodology.
Results
32 men [median (med) age 45 years; 16 White, 15 Black, 7 Latino] with HIV+ KS were enrolled. Baseline med CD4 was 274 cells/μL. 9 pts had no prior systemic KS therapy. Pts received a med of 10 cycles of pembro. 2 pts completed 35 cycles and/or 2 years of treatment, 6 have ongoing treatment, and 24 stopped treatment before 35 cycles [progressive disease (9), unacceptable toxicity (5), declined further treatment (3), death (1), other reasons (6)]. Med CD4 increase at end-of-treatment was 50 cells/μL (p=0.046). 13 pts (41%) had grade (G) ≥2 pembro-related treatment-emergent adverse events (AE), including 1 previously reported pt who died of polyclonal HHV8-related B cell lymphoproliferation. 10 (31%) pts had ≥1 immune-mediated AE (imAE) [G1 (1), G2 (5), G3 (4)] with 7 (22%) requiring systemic steroids. Of the 28 evaluable pts, 17 had a partial response (including 6 with CD4 <200 cells/μL), 8 had stable disease, and 3 had progressive disease as best response to pembro. The overall response rate (ORR) was 60.7% (95% CI: 40.6-78.5) and did not differ by CD4. Notably, the ORR was 85.7% (95% CI: 42.1-99.6) in pts without prior KS therapy. Med PFS was 28.2 mo (95% CI: 4.2-non-calcuable). The KM probability estimate of a DOR ≥ 12 months was 91.7% (95% CI: 53.9-98.7).
Conclusions
Pembro leads to a durable, high response rate, particularly as first systemic KS therapy, and is associated with CD4 immune reconstitution. Although 31% of pts had imAEs, they were successfully managed following standard guidelines.
Clinical trial identification
NCT02595866.
Editorial acknowledgement
Legal entity responsible for the study
Fred Hutchinson Cancer Center.
Funding
National Cancer Institute of the National Institutes of Health and Merck Sharp & Dohme Corp.
Disclosure
K. Lurain: Financial Interests, Institutional, Other, Financial support to NCI for clinical trial: BMS, CTI BioPharma, EMD Serrono; Financial Interests, Institutional, Other, Drug supplied for clinical trial: Merck, Eli Lily; Financial Interests, Institutional, Other, Drug supplied for preclinical studies: Lentigen; Financial Interests, Institutional, Other, Financial support to NCI for preclinical studies: Janssen. R. Ramaswami: Financial Interests, Institutional, Other, Collaborative agreement for funding of clinical trial: BMS-Celgene; Financial Interests, Institutional, Other, Collaborative agreement for supply of study drug for clinical trial: CTI Biopharma; Financial Interests, Institutional, Other, Collaborative research agreement for funding of study to institution.: EMD-Serono. G. Goyal: Financial Interests, Personal, Advisory Board: Opna Bio LLC; Financial Interests, Personal, Other, Consultancy: 2nd.MD; Financial Interests, Institutional, Local PI: Sutro Biopharma, Viracta therapeutics, SeaGen. M. Menon: Financial Interests, Institutional, Coordinating PI, Research funds to my institution: Cepheid, Roche; Financial Interests, Institutional, Coordinating PI, Research Funds to my institution: GSK; Non-Financial Interests, Member: American Society of Clinical Oncology (ASCO). M. Wagner: Financial Interests, Personal, Advisory Board, Scientific advisory board: Adaptimmune, Deciphera, Epizyme, Aadi. N. Bhardwaj: Financial Interests, Personal, Advisory Board: Novartis, curevac, Breakbio, Genotwin, carisma, ATP; Financial Interests, Institutional, Full or part-time Employment, Professor of Hematology and Oncology: Icahn School of Medicine; Financial Interests, Personal, Full or part-time Employment, extramural member: Parker Institute for Cancer therapy; Financial Interests, Personal, Stocks/Shares: Apricity, Primevax, Vaccitech, Rome therapeutics; Financial Interests, Personal, Other, licensed technology: CellBioengines; Financial Interests, Institutional, Coordinating PI: Merck; Non-Financial Interests, Principal Investigator, grants: NIH; Other, Other, Board of Directors: AACR; Other, Other, Boards of Scientific Councillors: Cancer Research Institute. M. Abdul-Hay: Financial Interests, Personal, Advisory Board: Takeda, Incyte, Kite, Jazz, Daiichi Sankyo, Rigel; Financial Interests, Institutional, Coordinating PI: Janssen; Financial Interests, Institutional, Local PI: servier, Janssen. R. Yarchoan: Financial Interests, Institutional, Other, CRADA with NCI to do preclinical and clinical research. Funds, drug, and proprietary information provided.: BMS; Financial Interests, Institutional, Other, Drug to NCI for clinical trial.: Merck and Co.; Financial Interests, Institutional, Other, Drug and proprietary information to NCI under CRADA in support of clinical trial.: EMD Serono; Financial Interests, Institutional, Other, Drug and proprietary information to NCI in support of clinical trial: Eli Lilly; Financial Interests, Institutional, Other, CRADA with NCI providing funds, proprietary information, and drug to support preclinical and clinical research.: CTI Biopharma; Financial Interests, Institutional, Other, Drug and proprietary information to conduct preclinical research.: Janssen Pharmaceutical; Other, Other, R. Yarchoan is a co-inventor on US Patent 10,001,483 entitled: NIH. S.P. Fling: Financial Interests, Institutional, Funding, Industry provided funds in salary support and research for CITN clinical trials.: Merck, Revimmune. Q. Lu: Financial Interests, Institutional, Full or part-time Employment, I am the employee of the above company which was compensated for the works I did (including statistical analysis and review of abstract) for this submitted abstract: Cytel Singapore Pte. Ltd., Singapore. T.S. Uldrick: Financial Interests, Personal, Full or part-time Employment: Regeneron; Financial Interests, Personal, Stocks/Shares: Regeneron; Financial Interests, Institutional, Coordinating PI, Supported clinical trial.: Merck, Roche; Financial Interests, Institutional, Other, Supported clinical trial: Celgene/BMS. All other authors have declared no conflicts of interest.
Resources from the same session
1830P - CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, open-label, dose-escalation and dose expansion study
Presenter: Kaiwen Li
Session: Poster session 15
1831P - Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?
Presenter: Lisa Horvath
Session: Poster session 15
1832P - Centralized screening for homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A feasibility study from a multicenter Spanish cohort
Presenter: Javier Freire
Session: Poster session 15
1833P - Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial
Presenter: Channing Paller
Session: Poster session 15
1834P - Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
Presenter: Arun Azad
Session: Poster session 15
1835P - A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)
Presenter: Shahneen Sandhu
Session: Poster session 15
1836P - Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
Presenter: Maria Ruiz Vico
Session: Poster session 15
1837P - Assessing PSA
Presenter: Susan Halabi
Session: Poster session 15
1839P - Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers
Presenter: George Seed
Session: Poster session 15